Technology

The European Commission is gathering information from third parties about Oracle's licensing practices, but a Commission spokesperson confirmed no formal investigation has been opened and no Oracle case number appears in the public register. The exercise follows the Commission's July 2026 acceptance of legally binding SAP commitments on on-premise software aftermarket support, which apply globally for ten years and carry a potential fine of up to 10% of SAP's worldwide annual turnover for breach. Enterprise software customers can use the SAP outcome as a concrete reference point for the types of contractual flexibility regulators may pursue, while the Oracle matter remains at an early, unresolved stage.

On September 2, 2026, CISA added seven confirmed-exploited vulnerabilities to its Known Exploited Vulnerabilities catalog, spanning products from SonicWall, JFrog, Sangoma, and three open-source projects, with federal agencies required to patch or mitigate five of them by September 5. The two SonicWall SMA1000 flaws — a pre-authentication SSRF and a post-authentication remote code execution vulnerability — carry no available workaround, meaning affected organizations must upgrade firmware or discontinue use. Five of the seven CVEs also require forensic triage, and patches are available for all seven products.

Studsvik, GE Vernova Hitachi, Samsung C&T, GE Vernova Financial Services, and DS Investment Partners have entered an exclusive development agreement to advance a 1.2 GW nuclear program in Sweden, targeting first-unit operation in the mid-2030s. The agreement initiates commercial, technical, regulatory, and financing work but does not constitute a final investment decision, authorize construction, or identify a confirmed Swedish site. Two candidate locations — Studsvik's existing Nyköping facility and the Målma site in Valdemarsvik — have each had permit applications submitted, but neither has received government approval, an environmental permit, or a nuclear activities license.

Anteris received FDA Investigational Device Exemption authorization in November 2025 to run PARADIGM, a randomized trial comparing its DurAVR transcatheter heart valve against approved commercial valves in roughly 1,650 patients across the U.S., Europe, and Canada. The IDE permits clinical data collection only and does not constitute market approval; first U.S. patients were treated in May 2026, with active recruitment confirmed in the United States, Denmark, and the Netherlands as of August 2026. Primary completion is estimated for December 2027, with full study completion projected through March 2038.

Nyxoah's ACCCESS trial reported that 77.2% of implanted patients with complete concentric collapse met the AHI responder threshold at 12 months, with an 87.7% ODI responder rate and zero device-related serious adverse events across 47 patients. The figures come from a company press release without confidence intervals or secondary endpoint data, and the ClinicalTrials.gov registry does not list a separate safety endpoint, leaving a documentation gap to be resolved when full results are presented in October 2026. Nyxoah is preparing a PMA supplement to expand Genio's FDA indication to CCC patients, but no regulatory approval has been granted.